Skip to content
Adrienne Monson – Lifestyle
Author:
Mission Therapeutics
Mission Therapeutics strikes deal worth up to $292 million for Dimerix Ltd to develop Acute Kidney Injury asset MTX652, sharpens focus on its CNS pipeline
July 17, 2026